ClinicalTrials.gg
CompletedNCT01689363H001-A2Updated Jan 20, 2017Results posted

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

A Phase 2 interventional study of Hyaluronidase and Histamine in Allergic Skin Reaction, sponsored by Amphastar Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-20.

Sponsored by Amphastar Pharmaceuticals, Inc. · Phase 2, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 301 studies in Hypersensitivity with a site in United States — 33 open to participants now, 41 under way, 1 of them phase 3. Hypersensitivity · United States.

Enrollment
46th of 220
253 · median 60
Started
2012
with 11 others
Phase 2
49 of 301
8 open now
Registered
146th of 301
by date

Among the 301 studies in Hypersensitivity with a site in United States, this one is the 46th largest by enrollment of the 220 interventional ones that give a count, is one of 12 that started in 2012, is one of 49 in phase 2, and was the 146th registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

33 of the 301 studies in Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 301 studies in Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.

03

Conditions studied

  • Allergic Skin Reaction

Browse trials for

Keywords

  • hyaluronidase
  • enzymes with tissue spreading activity
  • allergic reaction
  • intradermal skin testing
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy volunteers of either gender; Those without cardiovascular gastrointestinal, hepatic, neurological, psychiatric, endocrine, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results, assessed according to the judgment of the Principal Investigator. A non-inclusive list which would not be exclusionary and define healthy individual for the purposes of this study are:

  • hypothyroidism,
  • stable hypertension except those subjects on beta blockers including ocular preparations,
  • seasonal/perennial allergic rhinitis if able to wash out of antihistamines,
  • stable, mild intermittent asthma (subjects using beta agonists as a monotherapy on an as-needed basis, excluding daily usage),
  • migraine if not taking excluded medications,
  • mild anxiety/depression if not taking excluded medications, and
  • mild arthritic conditions if not taking excluded medications.

    • Willingness and ability to sign an document;
    • 18 - 80 years of age;
    • Intact skin at the forearm ;
    • Female participants are currently practicing effective methods or abstinence.

Exclusion criteria

Exclusion Criteria:

  • Known allergy, or to hyaluronidase, thimerosal, edetate disodium (EDTA);
  • Use of medications within a duration considered to interfere with skin testing.
  • Known dermographism which may interfere with skin testing.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    Arm H

    Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)

    Drug: Hyaluronidase

  • Active comparator
    Arm P

    Intradermal injection of Histatrol (histamine base 0.1 mg/mL)

    Drug: Histamine

  • Placebo comparator
    Arm N

    Intradermal injection of saline (0.02 mL)

    Drug: Saline

Interventions

  • Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.

    Also known as: Amphadase®

  • Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.

    Also known as: Histatrol®

  • DrugSaline

    Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.

06

What researchers measure

Primary outcomes

  1. Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.

    Time frame: Up to 30 minutes after the final study drug injection

  2. Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.

    Time frame: Up to 30 minutes after the final study drug injection

Secondary outcomes

  1. Observed Wheal Size in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  2. Observed Erythema Size in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  3. Allergic Wheal Size in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  4. Allergic Erythema Size in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  5. Local Itchiness Rate in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  6. Erythema Responder Rate in the Per-Protocol Population (PPP)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  7. Observed Wheal Size in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  8. Observed Erythema Size in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  9. Allergic Erythema Size in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  10. Local Itchiness Rate in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  11. Erythema Responder Rate in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

  12. Allergic Wheal Size in the Intent-to-Treat Population (ITT)

    Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.

    Time frame: Up to 30 minutes after the final study drug injection

07

Results

Posted Jan 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneH, N, H, PH, N, P, HH, P, H, NH, P, N, HN, H, H, PN, H, P, HP, H, H, NP, H, N, H
Started3232323131313232
Completed3231323131313232
Not completed01000000
Withdrew: Protocol violation01000000

Outcome measures

PrimaryPositive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Number · participants
Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP)
participantsPer-Protocol Population (PPP)
Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP)0
PrimaryPositive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. A positive reaction consisted of: a) reaction appearing within 30 minutes of drug placement; b) wheal (\>8 mm) with or without pseudopods; c) reaction accompanying erythema; and d) reaction accompanying localized itching.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Number · participants
Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT)
participantsIntent-to-Treat Population (ITT)
Positive Allergic Reaction to Amphadase® in the Intent-to-Treat Population (ITT)7
SecondaryObserved Wheal Size in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Observed Wheal Size in the Per-Protocol Population (PPP)
mmArm HArm NArm P
Observed Wheal Size in the Per-Protocol Population (PPP)1.1 ± 2.61.7 ± 2.715.3 ± 4.9
SecondaryObserved Erythema Size in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Observed Erythema Size in the Per-Protocol Population (PPP)
mmArm HArm NArm P
Observed Erythema Size in the Per-Protocol Population (PPP)4.3 ± 7.00.6 ± 3.744.4 ± 11.7
SecondaryAllergic Wheal Size in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Allergic Wheal Size in the Per-Protocol Population (PPP)
mmArm HArm NArm P
Allergic Wheal Size in the Per-Protocol Population (PPP)0.1 ± 0.90.0 ± 0.015.2 ± 4.9
SecondaryAllergic Erythema Size in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Allergic Erythema Size in the Per-Protocol Population (PPP)
mmArm HArm NArm P
Allergic Erythema Size in the Per-Protocol Population (PPP)1.1 ± 5.00.0 ± 0.144.1 ± 11.8
SecondaryLocal Itchiness Rate in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Number · percentage of participants
Local Itchiness Rate in the Per-Protocol Population (PPP)
percentage of participantsArm HArm NArm P
Local Itchiness Rate in the Per-Protocol Population (PPP)7.71.1100.0
SecondaryErythema Responder Rate in the Per-Protocol Population (PPP)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Number · percentage of participants
Erythema Responder Rate in the Per-Protocol Population (PPP)
percentage of participantsArm HArm NArm P
Erythema Responder Rate in the Per-Protocol Population (PPP)51.48.7100.0
SecondaryObserved Wheal Size in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed wheal size is the greatest wheal diameter measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Observed Wheal Size in the Intent-to-Treat Population (ITT)
mmArm HArm NArm P
Observed Wheal Size in the Intent-to-Treat Population (ITT)1.5 ± 3.31.7 ± 2.814.1 ± 5.6
SecondaryObserved Erythema Size in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The observed erythema size is the greatest erythema diameter measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Observed Erythema Size in the Intent-to-Treat Population (ITT)
mmArm HArm NArm P
Observed Erythema Size in the Intent-to-Treat Population (ITT)5.4 ± 9.60.9 ± 4.541.5 ± 14.7
SecondaryAllergic Erythema Size in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic erythema size is the greatest erythema diameter with accompanying localized itching measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Allergic Erythema Size in the Intent-to-Treat Population (ITT)
mmArm HArm NArm P
Allergic Erythema Size in the Intent-to-Treat Population (ITT)2.1 ± 8.00.1 ± 1.934.0 ± 21.1
SecondaryLocal Itchiness Rate in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The local itchiness rate is the percentage of subjects that reported localized itching at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Number · percentage of participants
Local Itchiness Rate in the Intent-to-Treat Population (ITT)
percentage of participantsArm HArm NArm P
Local Itchiness Rate in the Intent-to-Treat Population (ITT)10.31.679.1
SecondaryErythema Responder Rate in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The erythema responder rate is the percentage of subjects that showed an erythema reaction at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Number · percentage of participants
Erythema Responder Rate in the Intent-to-Treat Population (ITT)
percentage of participantsArm HArm NArm P
Erythema Responder Rate in the Intent-to-Treat Population (ITT)53.811.197.6
SecondaryAllergic Wheal Size in the Intent-to-Treat Population (ITT)

Subjects received intradermal injections at 4 injection sites following a randomized configuration of study medications. Injection sites were monitored for any characteristic immediate reactions after the study drug injections. The allergic wheal size is the greatest wheal diameter with accompanying erythema and localized itching measured at the injection site(s) for a specific study drug injection.

Time frame:
Up to 30 minutes after the final study drug injection
Reported as:
Mean · mm
Allergic Wheal Size in the Intent-to-Treat Population (ITT)
mmArm HArm NArm P
Allergic Wheal Size in the Intent-to-Treat Population (ITT)0.5 ± 2.40.0 ± 0.711.5 ± 7.6

Adverse events

Collected over Signing of Informed Consent until Adverse Event Resolution/Stabilization (approximately 30 days). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm H—0/253 (0%)0/253 (0%)
Arm N—0/253 (0%)0/253 (0%)
Arm P—0/253 (0%)0/253 (0%)
All Arms—0/253 (0%)0/253 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Total Study Population
<=18 years7
Between 18 and 65 years239
>=65 years7
Age, Continuous
Age, Continuous(years)Total Study Population
Mean34.9 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Total Study Population
Female127
Male126
Region of Enrollment
Region of Enrollment(participants)Total Study Population
United States253
08

Study locations

5 sites
  • Amphastar Site 0022
    Eugene, Oregon 97401, United States
  • Amphastar Site 0023
    Lake Oswego, Oregon 97035, United States
  • Amphastar Site 0026
    Portland, Oregon 97202, United States
  • Amphastar Site 0038
    Renton, Washington 98057, United States
  • Amphastar Site 0034
    Seattle, Washington 98115, United States
09

References and documents

Publications

  • Barr J, Kirkpatrick N, Dick A, Leonard L, Hawksworth G, Noble DW. Effects of adrenaline and hyaluronidase on plasma concentrations of lignocaine and bupivacaine after peribulbar anaesthesia. Br J Anaesth. 1995 Dec;75(6):692-7. doi: 10.1093/bja/75.6.692. PubMed 8672315 ↗
  • Brydon CW, Basler M, Kerr WJ. An evaluation of two concentrations of hyaluronidase for supplementation of peribulbar anaesthesia. Anaesthesia. 1995 Nov;50(11):998-1000. doi: 10.1111/j.1365-2044.1995.tb05940.x. PubMed 8678264 ↗
  • Ahluwalia HS, Lukaris A, Lane CM. Delayed allergic reaction to hyaluronidase: a rare sequel to cataract surgery. Eye (Lond). 2003 Mar;17(2):263-6. doi: 10.1038/sj.eye.6700243. No abstract available. PubMed 12640426 ↗
  • Agrawal A, McLure HA, Dabbs TR. Allergic reaction to hyaluronidase after a peribulbar injection. Anaesthesia. 2003 May;58(5):493-4. doi: 10.1046/j.1365-2044.2003.03154_17.x. No abstract available. PubMed 12694021 ↗
  • Kempeneers A, Dralands L, Ceuppens J. Hyaluronidase induced orbital pseudotumor as complication of retrobulbar anesthesia. Bull Soc Belge Ophtalmol. 1992;243:159-66. PubMed 1302146 ↗
  • Minning CA Jr. Hyaluronidase allergy simulating expulsive choroidal hemorrhage. Arch Ophthalmol. 1994 May;112(5):585-6. doi: 10.1001/archopht.1994.01090170029012. No abstract available. PubMed 8185511 ↗
  • Szepfalusi Z, Nentwich I, Dobner M, Pillwein K, Urbanek R. IgE-mediated allergic reaction to hyaluronidase in paediatric oncological patients. Eur J Pediatr. 1997 Mar;156(3):199-203. doi: 10.1007/s004310050582. PubMed 9083759 ↗
  • Allergy testing. American College of Physicians. Ann Intern Med. 1989 Feb 15;110(4):317-20. No abstract available. PubMed 2578014 ↗
  • Poulsen LK. In vivo and in vitro techniques to determine the biological activity of food allergens. J Chromatogr B Biomed Sci Appl. 2001 May 25;756(1-2):41-55. doi: 10.1016/s0378-4347(01)00070-6. PubMed 11419727 ↗
  • Howard A, Mercer P, Nataraj HC, Kang BC. Bevel-down superior to bevel-up in intradermal skin testing. Ann Allergy Asthma Immunol. 1997 Jun;78(6):594-6. doi: 10.1016/s1081-1206(10)63222-x. PubMed 9207725 ↗
  • Barbaud A, Reichert-Penetrat S, Trechot P, Jacquin-Petit MA, Ehlinger A, Noirez V, Faure GC, Schmutz JL, Bene MC. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998 Jul;139(1):49-58. doi: 10.1046/j.1365-2133.1998.02313.x. PubMed 9764148 ↗
  • Fisher MM, Bowey CJ. Intradermal compared with prick testing in the diagnosis of anaesthetic allergy. Br J Anaesth. 1997 Jul;79(1):59-63. doi: 10.1093/bja/79.1.59. PubMed 9301390 ↗
  • Ruzicka T, Gerstmeier M, Przybilla B, Ring J. Allergy to local anesthetics: comparison of patch test with prick and intradermal test results. J Am Acad Dermatol. 1987 Jun;16(6):1202-8. doi: 10.1016/s0190-9622(87)70158-3. PubMed 3597862 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Nov 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2012
First posted
Sep 21, 2012
Start
Sep 2012
Primary completionActual
Nov 2012
CompletionActual
Dec 2012
Results first posted
Jan 20, 2017
Last update
Jan 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01689363
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Sep 21, 2012
Start date
Sep 2012
Primary completion
Nov 2012
Completion
Dec 2012
Results posted
Jan 20, 2017
Last update
Jan 20, 2017

Study contacts

Selina Su, MPH
study chair · A:mphastar Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronoglucosaminidase

Start the discussion